Plaque-type psoriasis affects the genital area in 7–42% of patients, and can impose significant quality of life (QoL) impairments. In this case, systemic treatment is recommended regardless of the affected body surface area. This real-world study compared treatment effects and patient-reported outcomes (PROs) between patients with and without genital lesions, undergoing apremilast treatment for 6 ± 1 months. Secondary analyses were conducted using data from the observational, retrospective, cross-sectional APPRECIATE study.